Celcuity Inc
CELC
NASDAQ
Biotechnology
$92.00
USD
+5.40 (+6.24%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $4.36B
Volume 1.3M
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-192.89M
TTM
-51.7%
YoY
Operating Cash Flow
$-172.49M
TTM
-68.7%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 6.4 | 3.8 | 7.9 | 11.6 | 17.4 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 36.1 | 44.0 | 42.8 | 49.2 | 50.5 |
Operating Income | -36.1 | -44.0 | -42.8 | -49.2 | -50.5 |
EBITDA | -36.1 | -44.0 | -42.8 | -49.2 | -50.5 |
Other Income / Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Other Income / Expense | -0.9 | -1.3 | -1.0 | -1.8 | -2.3 |
Income Before Income Taxes | -37.0 | -45.3 | -43.8 | -51.0 | -52.8 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -37.0 | -45.3 | -43.8 | -51.0 | -52.8 |
Consolidated Net Income / Loss | -37.0 | -45.3 | -43.8 | -51.0 | -52.8 |
Net Income Attributable to Common Shareholders | -37.0 | -45.3 | -43.8 | -51.0 | -52.8 |
Basic EPS | -$0.86 | -$1.04 | -$0.92 | -$0.97 | -$0.97 |
Diluted EPS | -$0.86 | -$1.04 | -$0.92 | -$0.97 | -$0.97 |
Basic Shares Outstanding | 43.1M | 43.7M | 47.6M | 52.7M | 54.5M |
Diluted Shares Outstanding | 43.1M | 43.7M | 47.6M | 52.7M | 54.5M |